Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
Authors not listed
Liaoning Chengda Biotechnology CO., LTD · 2025
Abstract
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients with chronic diseases, and elderly individuals) who receive their first post-exposure treatment following WHO category II or III rabies exposure. The control group will include 30 healthy adults with similar exposure.
Blood samples will be collected at Day 14 and Day 90 after completion of the full vaccination schedule to assess rabies virus neutralizing antibody seroconversion rates and titers. Immunogenicity and antibody persistence will be compared between the two groups. Additionally, all adverse events occurring within 30 minutes and within 7 days after each dose will be recorded to evaluate safety.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2025). Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations. <em>Liaoning Chengda Biotechnology CO., LTD</em>. https://clinicaltrials.gov/study/NCT07120464
Vancouver
Anonymous. Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations. Liaoning Chengda Biotechnology CO., LTD. 2025.
BibTeX
@misc{anon2025Clinic,
title = {Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations},
author = {Anonymous},
journal = {Liaoning Chengda Biotechnology CO., LTD},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Florida 2022
Open access · US-GOV
Yeast-derived Beta-glucan Supplementation on Antibody Response Following Influenza Vaccination: A Randomized, Placebo-controlled Study (M-Unity)
Ab&B Bio-tech Co., Ltd.JS 2023
Open access · US-GOV
A Randomized, Single-arm, Phase Ⅰ Clinical Trial to Evaluate the Safety of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried Vaccinated With Different Immunization Schedule in People Aged 10-60 Years
Alachua Government Services, Inc. 2009
Open access · US-GOV
A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years
Alachua Government Services, Inc. 2008
Open access · US-GOV
Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years
Abinopharm, Inc 2021
Open access · US-GOV
A Multi Center Two Part Study to Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
Beijing BeneWill Technology Development Co., Ltd 2026
Open access · US-GOV